Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer

Summary

The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.

Eligibility

Inclusion Criteria:

1. Aged between 18 and 79 years;
2. Received at least two cycles of neoadjuvant immunotherapy;
3. ECOG performance status score of 0;
4. Complete clinical information including imaging data available.

Exclusion Criteria:

1. Diagnosed with or suspected active autoimmune diseases;
2. Presence of EGFR/ALK sensitive mutations;
3. Pregnant or breastfeeding women;
4. Previous anti-tumor therapies including chemotherapy or radiotherapy;
5. History of organ transplantation or hematopoietic stem cell transplantation;
6. Interstitial pneumonia, pulmonary fibrosis, or severe emphysema;
7. Uncontrolled diabetes mellitus;
8. Uncontrolled hypertension.

Conditions4

Browse More Trials